Icon Group has almost 30 years’ experience in cancer research and now operates the largest private cancer clinical trials program in Australia. As part of Icon Group, Icon Cancer Centre Singapore is committed to providing access to research and clinical trials to patients across ASEAN.

We are also proud to announce that Icon Singapore has received the Australian Council on Healthcare Standards International (ACHSI) Evaluation and Quality Improvement Program (EQuIP) accreditation for research.

We believe patients across our centres deserve the opportunity to access clinical trials and the hope that they offer.

To find out more about the research that Icon is participating in, our team and achievements during 2023, please read the 2023 Icon Research Annual Report.

At Icon, our dedicated research program enables our patients to access new and emerging advances in cancer treatment, giving new hope and opportunities to patients and their families.

We run trials across various tumour types and haematological conditions, including chemotherapy, immunotherapy and radiation therapy trials. Icon also offers trials that aren’t directly connected to a treatment technique, but are focused on wellbeing and improving quality of life for our patients.

By providing access to a wide range of clinical trials across a multitude of cancer types, Icon helps to contribute to breakthroughs and advancements in cancer treatments for the benefit of current and future patients.